Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million (USD 13.9 million) in an angel financing round. The round saw participation from notable investors such as Kaitai Capital, Noah Capital, CAS Star, and Kunlun Capital. The funds raised will be directed towards clinical studies for the company’s Boron Neutron Capture Therapy (BNCT) system and the development of boron medicine.
Clinical Studies and BNCT System Development
The BNCT system developed by Huaboron Neutron Technology utilizes thermal/epithermal neutrons to capture and react with 10B elements in boron drugs that are enriched at the tumor site, effectively targeting and killing tumor cells. This innovative approach offers a non-invasive treatment method with several advantages over traditional radiotherapy, proton therapy, and heavy ion radiotherapy techniques.
Advantages of BNCT Over Traditional Radiotherapy
BNCT stands out due to its short treatment time, precise targeting capabilities, minimal side effects, proven clinical efficacy, and manageable costs. These benefits position BNCT as a promising alternative in the field of cancer treatment, potentially offering patients a more effective and less invasive option.-Fineline Info & Tech
